MAIN ARTICLE
From reliance on other regulators to independent judgment
Dr Li began a three-year appointment as Controller for Medical Products Regulation on October 20, 2026, following an international recruitment exercise. His experience at the FDA, and across the pharmaceutical sector, is an asset to a city seeking credibility beyond its borders. But the CMPR is not simply a new office with a celebrated director. It must build the ability to interrogate clinical evidence, assess benefit against risk, and take responsibility for its own conclusions.
The government’s roadmap, published in 2025 and incorporated into its 2026–2030 development plan, calls for phased primary evaluation beginning in 2026. An initial stage started on March 31, covering specified applications involving chemical entities already registered locally. Full independent assessment of new medicines is a 2030 goal, not a capability already available across all products today. That distinction matters for patients and investors interpreting reform announcements.
Hong Kong’s earlier “1+” mechanism, introduced in November 2023, lowered the usual requirement for relevant applications from two approvals in external reference jurisdictions to one, alongside specified local evidence and expert support. It helped reduce reliance on multiple foreign decisions, but it is not the same as completely independent primary review based on original data. Moving between these models entails major changes in staffing, legal accountability and regulatory culture.















